Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 juin 2016 17h35 HE | Source: ApeX Therapeutics, Inc.

ApeX Therapeutics Files IND to Initiate Phase 1 Study to Evaluate the Tolerability and Anti-Tumor Effects of APX3330

INDIANAPOLIS, IN--(Marketwired - June 20, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced the filing of an Investigation New...
12 mai 2016 16h00 HE | Source: Apex Therapeutics, Inc.

ApeX Therapeutics and Researchers at Indiana University to Present Phase 1 Clinical Plan for APX3330 and Novel Approach to Addressing Therapeutic Resistance at AACR Pancreatic Cancer Meeting

INDIANAPOLIS, IN--(Marketwired - May 12, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, in collaboration with researchers at Indiana...
12 avr. 2016 08h00 HE | Source: Apex Therapeutics, Inc.

ApeX Therapeutics to Present Ability of APX3330 to Target Multiple Oncogenic Transcription Factors in Pancreatic Cancer as Single Agent or Combination Therapy at AACR Annual Meeting

INDIANAPOLIS, IN--(Marketwired - April 12, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced three poster presentations...